Study of Diclofenac Capsules to Treat Pain Following Bunionectomy
Launched by IROKO PHARMACEUTICALS, LLC · Oct 27, 2011
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is male or female between 18 and 65 years of age
- • For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
- • Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures
- • Patient must be willing to stay at the study site ≥ 72 hours
- Exclusion Criteria:
- • Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs
- • Patient has a current disease or history of a disease that will impact the study or the patient's well-being
- • Patient has used or intends to use any of the medications that are prohibited by the protocol
- • Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test
- • Patient has taken another investigational drug within 30 days prior to screening
About Iroko Pharmaceuticals, Llc
Iroko Pharmaceuticals, LLC is a biopharmaceutical company dedicated to advancing innovative pain management solutions through the development of novel therapeutic products. With a strong focus on utilizing proprietary technologies to enhance the safety and efficacy of non-opioid analgesics, Iroko aims to address the pressing challenges of pain relief while minimizing the risks associated with traditional pain medications. Committed to rigorous clinical research and a patient-centered approach, Iroko Pharmaceuticals strives to improve the quality of life for patients suffering from acute and chronic pain conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pasadena, Maryland, United States
Austin, Texas, United States
Phoenix, Arizona, United States
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Michael Golf, DPM
Principal Investigator
Premier Research Group Limited
Ira Gottlieb, DPM
Principal Investigator
Chesapeake Research Group, LLC
Kyle Patrick, DO
Principal Investigator
Premier Research Group Limited
S. Thomas Schiffgen, DPM
Principal Investigator
Premier Research Group Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials